Ruling against Wyeth could undermine FDA

January 2009
Healthcare Risk Management;Jan2009, Vol. 31 Issue 1, p7
The article focuses on a court ruling on a case against Wyeth regarding drug labeling, which is said to threaten the authority of the U.S. Food and Drug Administration.


Related Articles

  • New drug labeling rules take effect with extensions.  // Packaging Digest;Aug94, Vol. 31 Issue 9, p1 

    Reports on the extension on parts of the drug labeling rules set by the Food and Drug Administration (FDA) effective on August 3, 1994. Exemption ruling for manufacturers using 100 percent automated product labeling system; Labelings excluded from the special cut labeling controls.

  • FDA optimiistic on use of new labeling.  // Medical Marketing & Media;Sep2001, Vol. 36 Issue 9, p34 

    Reports on the projected outcome of the drug labeling initiative of the Food and Drug Administration in the U.S. Impact of the initiative on physician behavior; Viability of the initiative to reduce drug risks to patients; Basis of the initiative.

  • AAFP represented at kickoff for improved drug labeling. Sweeney, Rosemarie; Rose, Verna L. // American Family Physician;9/15/1997, Vol. 56 Issue 4, p1023 

    Announces the initiative that require improved labeling of drugs used frequently for children in the United States. Requirement on the proposed regulation of the Food and Drug Administration (FDA).

  • FDA delays on generic labeling rule. Vaczek, David // Medical Marketing & Media;Jan2015, Vol. 50 Issue 1, p12 

    The article reports that U.S. Food and Drug Administration (FDA) has been waiting for the release of a proposed rule that will allow generic drug manufacturers to use process for updating drug labels used by branded drugmakers.

  • New drug labels.  // Mayo Clinic Health Letter;Feb2000, Vol. 18 Issue 2, p3 

    Reports on the drug label requirements issued by the United States Food and Drug Administration for over-the-counter medicines. Use of simple language in large-type letters; List of active and inactive ingredients; Same requirement for dietary supplements.

  • FDA to require imprints on Rx/OTC tablets and capsules. Conlan, Michael F. // Drug Topics;10/25/93, Vol. 137 Issue 20, p68 

    Reports on the Food & Drug Administration rule requiring prescription and over-the-counter tablets and capsules to be imprinted with product-specific identification codes. Date of effectivity; Exemptions; Public health benefits of imprinted drug codes.

  • More free speech for off-label uses. Greenberg // Packaging Digest;Sep99, Vol. 36 Issue 10, p28 

    Elaborates on a court's ruling declaring the Food and Drug Administration (FDA) Modernization Act of 1997 a violation of the rights of manufacturers to disseminate information relating to off-label FDA-approved drugs. FDA guidelines restricting the speech of manufacturers; Factors that examines...

  • FDA orders labeling changes for ESAs. Silver, Samuel // Hem/Onc Today;8/25/2008, Vol. 9 Issue 15, p1 

    The article reports on the order issued by the U.S. Food and Drug Administration (FDA) for the safety labels of darbepoetin alfa and epoetin alfa to indicate that they could only be administered in patients whose hemoglobin level is <10 grams/deciliter (g/dL). The labels should also state that...

  • Abuse leads to OxyContin labeling change.  // Medical Marketing & Media;Sep2001, Vol. 36 Issue 9, p35 

    Reports on the move of the Food and Drug Administration to change the tablet labeling of OxyContin (oxycodone HCI controlled-release) from Purdue Pharma LP in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics